Cancer News and Research

Latest Cancer News and Research

Crucial link between protein synthesis and autism spectrum disorders

Researchers from McGill University and the University of Montreal have identified a crucial link between protein synthesis and autism spectrum disorders (ASD), which can bolster new therapeutic avenues.

22 Nov 2012

Walter and Eliza Hall Institute researcher wins 2012 Victoria Prize for Science and Innovation

Professor Terry Speed, a senior researcher at the Walter and Eliza Hall Institute of Medical Research, was today awarded a 2012 Victoria Prize for Science and Innovation.

22 Nov 2012

Heidelberg researchers uncover function of specific molecular chaperones

Clumped proteins can be dissolved with the aid of cellular repair systems - a process of critical importance for cell survival especially under conditions of stress. Heidelberg researchers have now decrypted the fundamental mechanism for dissolving protein aggregates that involves specific molecular chaperones.

22 Nov 2012

Kidney tumors may be smarter than previously thought

New research has found there are several different ways that kidney tumours can achieve the same result - namely, grow.

22 Nov 2012

MicroRNAs in ovarian cancer cells promote tumor growth

Unraveling the mechanism that ovarian cancer cells use to change normal cells around them into cells that promote tumor growth has identified several new targets for treatment of this deadly disease.

22 Nov 2012

Homing beacon drugs can kill cancer cells

A medical researcher with the University of Alberta and his team just published their findings about their work on developing 'homing beacon drugs' that kill only cancer cells, not healthy ones, thanks to nano-technology.

22 Nov 2012

UPR pathway helps tumor cells escape apoptosis during development of lymphoma

A pathway called the "Unfolded Protein Response," or UPR, a cell's way of responding to unfolded and misfolded proteins, helps tumor cells escape programmed cell death during the development of lymphoma.

21 Nov 2012

Rexahn's quinoxalinyl-piperazine compounds receive U.S. patent

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company dedicated to developing and commercializing first-in-class oncology therapeutics, today announced that it has been issued a United States patent (No. 8,314,100), titled "1-[6,7-substituted alkoxyquinoxalinyl) aminocarbonyl]-4-(hetero) arylpiperazine derivatives."

21 Nov 2012

Regorafenib able to control resistant gastrointestinal stromal tumor

A new targeted drug demonstrated its ability to control metastatic gastrointestinal stromal tumor, an uncommon and life-threatening form of sarcoma, after the disease had become resistant to all existing therapies, report investigators at Dana-Farber Cancer Institute who led the worldwide clinical trial.

21 Nov 2012

Viewpoints: Protecting us from counterfeit medicines; Governors making excuses on insurance exchanges?; Simpson-Bowles and the health law

HHS has made it clear that after federally operated exchanges are up and running, states may eventually take over operations. This seems like wasted effort. States have the information they need to move on insurance exchanges. Governors who care about fiscal responsibility, strong state government and the basic welfare of their residents would do well to get with the program.

21 Nov 2012

Alternatives to colonoscopy for monitoring colorectal cancer risk

Researchers have found that there are effective alternatives to colonoscopy screening for managing people who have received an initial negative colonoscopy result for colorectal cancer.

21 Nov 2012

Watch-and-wait approach feasible following adjuvant therapy for rectal cancer

Patients with rectal cancer managed conservatively following a complete response to chemoradiotherapy achieve similar rates of disease control as those who undergo rectal resection, research shows.

21 Nov 2012

Exercise relieves cancer fatigue

A review of studies spanning 45 years shows that exercise, particularly aerobic rather than strength- or flexibility-based training, improves fatigue in cancer patients.

21 Nov 2012

Rituximab may help patients with aPL-related clinical problems

Rituximab, a drug used to treat cancer and arthritis, may help patients with antiphospholipid antibodies (aPLs) who suffer from aPL-related clinical problems that do not respond to anticoagulation, such as cardiac disease and kidney disease, according to a new study by rheumatology researchers at Hospital for Special Surgery. The study appears online ahead of print, in the journal Arthritis and Rheumatism.

21 Nov 2012

UNSW-developed nanoparticle could improve effectiveness of chemotherapy for neuroblastoma

In a world-first, researchers from the Australian Centre for Nanomedicine at the University of New South Wales (UNSW) in Sydney have developed a nanoparticle that could improve the effectiveness of chemotherapy for neuroblastoma by a factor of five.

21 Nov 2012

Discovery of DKK1-WNT pathway reveals new drug targets for Alzheimer's

The discovery of the molecular pathway that drives the changes seen in the brains of Alzheimer's patients is reported today, revealing new targets for drug discovery that could be exploited to combat the disease. The study gives the most detailed understanding yet of the complex processes leading to Alzheimer's.

21 Nov 2012

New polymer nanoparticles can generate heat and kill colorectal cancer cells

Researchers at Wake Forest Baptist Medical Center have modified electrically-conductive polymers, commonly used in solar energy applications, to develop revolutionary polymer nanoparticles (PNs) for a medical application. When the nanoparticles are exposed to infrared light, they generate heat that can be used to kill colorectal cancer cells.

21 Nov 2012

Gabrielle's Angel Foundation announces recipients of new collaborative grants for cancer research

Gabrielle's Angel Foundation for Cancer Research today announced grant recipients of its first-ever Collaborative Research grant program. The inaugural awards total $800,000 for two groundbreaking research initiatives that span the medical capitals of New York, Boston and Chicago.

21 Nov 2012

Acetylon's ective histone deacetylase inhibitors to be showcased at 54th ASH annual meeting

Acetylon Pharmaceuticals Inc., a leader in targeted epigenetic drug discovery and development for enhanced therapeutic outcomes, today announced that its selective histone deacetylase (HDAC) inhibitors will be featured in five posters and one oral presentation at the 54th Annual Meeting of the American Society of Hematology (ASH), taking place December 8-11, 2012, in Atlanta, Georgia.

21 Nov 2012

Fujirebio, Thermo Fisher sign license agreement for broad availability of PCT testing

Thermo Fisher Scientific Inc., the world leader in serving science, today announced it has signed a long-term license agreement with Fujirebio Inc. to make its biomarker assay Procalcitonin (PCT) available on the Lumipulse family of laboratory instruments, using the chemiluminescent enzyme immunoassay (CLEIA) technology.

From Thermo Fisher Scientific Inc. 21 Nov 2012